Patients with BRAF V600E mutation and higher S100B level in first postoperative plasma sample experienced the highest probability of melanoma recurrence (83.3% vs. 14.3%, resp., p = 0.001) and the worst prognosis with the shortest DFI (21.1 months vs. median not reached, p = 0.001) and OS (26.6 months vs. median not reached, p = 0.001) compared to those with BRAF WT and lower S100B concentration (Figure 5A,B, Table 3). Here, S100B is linked to melanoma.